DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)

Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Micardis® (Drug); MicardisPlus® (Drug)

Phase: N/A

Status: Completed

Sponsored by: Boehringer Ingelheim

Summary

Study to evaluate efficacy and tolerability of Micardis/MicardisPlus under usual daily-practice prescribing-conditions with emphasis on effects on endorgan damage in the clientele of cardiologists, nephrologists, and diabetologists

Clinical Details

Official title: Micardis / MicardisPlus PROTEKT (Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases)

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome:

Change in systolic blood pressure (SBP)

Change in diastolic blood pressure (DBP)

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Age >= 18 years

Exclusion Criteria:

- Age < 18 years

Locations and Contacts

Additional Information

Starting date: September 2003
Last updated: October 10, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017